ABSTRACT

Besides obesity, there are limited studies regarding the relationship between the individual components of metabolic syndrome and wheezing. It is largely unknown whether the coexistence of other metabolic syndrome components has additive effects on wheezing in the adult population. The association between the individual components of metabolic syndrome and current wheezing was evaluated in adults using data from the Korea National Health and Nutrition Examination Survey from 2008 to 2012. Subjects with metabolic syndrome more frequently had wheezing during the past 12 months (current wheezing) (adjusted odds ratio [aOR] = 1.56; 95% confidence interval [CI] = 1.37–1.77) and wheezing during exercise in the past 12 months (aOR = 1.59; 95% CI = 1.37–1.84). Of the individual metabolic syndrome components, central obesity (aOR = 1.48; 95% CI = 1.31–1.66) and low high-density lipoprotein (HDL) cholesterol (aOR = 1.18; 95% CI = 1.05–1.34) were significantly associated with current wheezing. There were no significant associations between the other components of metabolic syndrome (high triglyceride level, blood pressure, and fasting plasma glucose level) and the presence of current wheezing. In addition, the association was much higher when both central obesity and low HDL cholesterol were present together compared to when either of the conditions was present alone (aOR = 1.67; 95% CI = 1.44–1.94). There is a significant association between metabolic syndrome and current wheezing in Korean adults. Of the components of metabolic syndrome, low HDL cholesterol and central obesity are independently and additively associated with the increased rate of current wheezing.

Keywords: Metabolic syndrome; obesity; body mass index; lipoprotein, HDL; triglycerides; dyslipidemia; asthma; wheezing

INTRODUCTION

Metabolic syndrome is a cluster of metabolic conditions including abdominal obesity, elevated blood pressure (BP), dysregulated glucose level, and dyslipidemia (elevated triglyceride...
level and low high-density lipoproteins (HDL) cholesterol.\textsuperscript{13} The prevalence of metabolic syndrome has been increasing worldwide, and this condition is associated with various chronic diseases such as cardiovascular disease and diabetes mellitus (DM).\textsuperscript{13} Although the pathogenic mechanism is not clearly understood, obesity, which is a significant component of metabolic syndrome, is considered a possible risk factor for these chronic diseases.\textsuperscript{2,4}

In addition to the relationship between metabolic syndrome and cardiovascular disease/DM, previous studies have shown an association between asthma and metabolic syndrome.\textsuperscript{5,6} Of several components known to comprise metabolic syndrome, obesity is a well-known factor that is associated with wheezing, a major symptom in asthmatic patients.\textsuperscript{7,8} One study conducted on elderly patients over 65 years of age reported that waist circumference and low HDL cholesterol increased the risk of asthma; however, few studies assessed the relationship between metabolic syndrome components other than obesity and wheezing. In addition, it is largely unknown whether the co-existence of other metabolic syndrome components has additive effects on wheezing in the adult population.\textsuperscript{10} Consequently, more evidence is needed to demonstrate the relationship between wheezing and the individual components of metabolic syndrome.

Therefore, our study aimed to investigate the relationship between wheezing and the individual components of metabolic syndrome in Korean adults using a nationally representative health survey database.

**Materials and METHODS**

**Study subjects**

The Korea National Health and Nutrition Examination Survey (NHANES) is a population-based, cross-sectional survey of health and nutrition conducted by the Korean Ministry of Health and Welfare. Participants were randomly selected through a stratified, multistage, probability sampling method. Here, we analyzed the data from subjects at least 19 years of age who participated in the Korea NHANES 2008–2012 study (n = 34,670). We excluded 2,531 subjects with missing values for the following questionnaire questions: “Have you ever been diagnosed with asthma by a physician?” or “Have you had wheezing or whistling sounds while breathing during the past 12 months?”. Thereafter, we further excluded 1,664 subjects with missing values for any component of metabolic syndrome. Finally, 30,475 subjects were included in this study (Fig. 1).

**Measurements**

Data on age, sex, body mass index (BMI), waist circumference, and smoking history were obtained from the Korea NHANES database. Waist circumference was measured 3 times, and the mean value was used in the analysis. BP was tested in a seated position and was measured 3 times following at least 5-minute rest between measurements. The lowest measurement was used in the analysis.

Blood samples were obtained after an overnight fast (> 8 hours). Total cholesterol, triglyceride (TG), HDL cholesterol, and fasting plasma glucose (FPG) levels were analyzed via enzymatic methods using a Hitachi Automatic Analyzer 7600 (Hitachi, Tokyo, Japan) in a certified central laboratory (Neodin Medical Institute, Seoul, Korea).
Definitions

BMI was categorized as follows: underweight (< 18.5 kg/m²), normal weight (18.5–22.9 kg/m²), overweight (23.0–24.9 kg/m²), obese (25.0–29.9 kg/m²), and severely obese (≥ 30 kg/m²). According to the new criteria of the International Diabetes Federation (IDF) published in 2006, 11 patients were defined as having metabolic syndrome when they had central obesity plus 2 or more of the following criteria: 1) raised TG level ≥ 150 mg/dL or specific treatment for this lipid abnormality; 2) reduced HDL cholesterol: < 40 mg/dL in males and < 50 mg/dL in females or specific treatment for this lipid abnormality; 3) raised BP: systolic BP ≥ 130 mmHg, diastolic BP ≥ 85 mmHg, or treatment of previously diagnosed hypertension; 4) elevated FPG ≥ 100 mg/dL; and 5) previously diagnosed type 2 DM. Central obesity was defined as a waist circumference of at least 90 cm for Asian men and at least 80 cm for Asian women.

Asthma status was evaluated using the following categories: “lifetime asthma,” “physician-diagnosed asthma,” “current asthma,” “current wheezing,” or “current exercise-induced wheezing.” Subjects who responded “yes” to “Have you ever had asthma during a lifetime?” “Have you ever been diagnosed with asthma by a physician?” “Are you currently having asthma?” “Have you had wheezing or whistling sounds while breathing during the past 12 months?” “Have you had wheezing or whistling sounds while breathing during or after exercise in the past 12 months?” were defined as having “lifetime asthma,” “physician-diagnosed asthma,” “current asthma” “current wheezing,” and “current exercise-induced wheezing,” respectively.

Statistical analysis

Data are presented as weighted mean ± standard deviation or weighted percentage (standard error). To evaluate the association between the presence of metabolic syndrome and asthma status/wheezing in the previous year, we employed a multivariable logistic regression model in which age, sex, and smoking status were included. We further evaluated the association between the individual components of metabolic syndrome and the presence of wheezing in the previous year using multivariable logistic regression. Consequently, the components
of metabolic syndrome age, sex, and smoking history were inserted in model 1. In model 2, all components of metabolic syndrome, age, sex, and smoking history were inserted. All data were analyzed using Statistical Package for the Social Sciences (SPSS) 21.0 for Windows (SPSS Inc., Chicago, IL, USA).

RESULTS

Baseline characteristics of the study population
The baseline characteristics of the study subjects are summarized in Table 1. Subjects with metabolic syndrome were older (mean 53.7 vs. 42.4 years, \( P < 0.001 \)) than those without. Females (57.5% vs. 48.2%, \( P < 0.001 \)) and never-smokers (56.7% vs. 52.0%, \( P < 0.001 \)) were more frequent in subjects with metabolic syndrome compared to those without. Those with metabolic syndrome were more likely to be obese or severely obese (75.3% vs. 21.0%, \( P < 0.001 \)). Compared to subjects without subjects with metabolic syndrome had greater waist circumference (91.9 vs. 78.3 cm, \( P < 0.001 \)) and higher blood pressure (systolic BP: 128.0 vs. 114.8 mmHg, \( P < 0.001 \); diastolic BP: 81.6 vs. 75.3 mmHg, \( P < 0.001 \)) than those without.

Table 1. Clinical and demographic characteristics of the patients

| Characteristics | All participants (n = 30,475*) | Non-metabolic syndrome (n = 23,432*) | Metabolic syndrome (n = 7,043*) | \( P \) value* |
|-----------------|-------------------------------|------------------------------------|--------------------------------|---------------|
| Age (yr)        | 44.7 ± 0.17                   | 42.4 ± 0.17                        | 53.7 ± 0.26                   | < 0.001       |
| 19–29           | 19.9 (0.4)                    | 21.6 (0.5)                         | 5.0 (0.5)                     |               |
| 30–39           | 21.4 (0.4)                    | 23.4 (0.5)                         | 13.5 (0.6)                    |               |
| 40–49           | 22.2 (0.4)                    | 22.5 (0.4)                         | 21.1 (0.7)                    |               |
| 50–59           | 17.8 (0.3)                    | 16.2 (0.3)                         | 24.0 (0.7)                    |               |
| 60–69           | 10.5 (0.2)                    | 8.1 (0.2)                          | 20.0 (0.5)                    |               |
| ≥ 70            | 8.2 (0.2)                     | 6.1 (0.2)                          | 16.4 (0.5)                    |               |
| Sex             |                               |                                    |                               | < 0.001       |
| Male            | 50.0 (0.3)                    | 51.8 (0.4)                         | 42.5 (0.7)                    |               |
| Female          | 50.0 (0.3)                    | 48.2 (0.4)                         | 57.5 (0.7)                    |               |
| Smoking status  |                               |                                    |                               | < 0.001       |
| Current smoker  | 27.1 (0.3)                    | 28.0 (0.4)                         | 23.5 (0.7)                    |               |
| Ex-smoker       | 19.8 (0.3)                    | 19.8 (0.3)                         | 19.6 (0.6)                    |               |
| Never-smoker    | 53.0 (0.3)                    | 52.0 (0.4)                         | 56.7 (0.8)                    |               |
| BMI (kg/m²)     |                               |                                    |                               | < 0.001       |
| Underweight (< 18.5) | 4.7 (0.2)                | 5.9 (0.2)                          | 0 (0)                         |               |
| Normal (18.5–22.9) | 39.9 (0.4)                | 48.5 (0.4)                         | 5.6 (0.3)                     |               |
| Overweight (23.0–24.9) | 23.3 (0.3)                | 24.4 (0.3)                         | 18.9 (0.8)                    |               |
| Obesity (25.0–29.9) | 27.6 (0.3)                | 19.3 (0.3)                         | 60.7 (0.8)                    |               |
| Severe obesity (≥ 30) | 4.3 (0.2)                | 1.7 (0.1)                          | 14.6 (0.6)                    |               |
| Comorbidities   |                               |                                    |                               | < 0.001       |
| Hypertension    | 16.8 (0.3)                    | 10.7 (0.3)                         | 41.2 (0.8)                    |               |
| Diabetes        | 6.2 (0.2)                     | 3.7 (0.1)                          | 16.1 (0.5)                    |               |
| Physical measurement |                       |                                    |                               | < 0.001       |
| Waist (cm)      | 81.0 ± 0.10                   | 78.3 ± 0.09                        | 91.9 ± 0.11                   | < 0.001       |
| Systolic BP (mmHg) | 117.5 ± 0.17                 | 114.8 ± 0.17                       | 128.0 ± 0.28                  | < 0.001       |
| Diastolic BP (mmHg) | 76.5 ± 0.01                 | 75.3 ± 0.13                        | 81.6 ± 0.18                   | < 0.001       |
| Laboratory findings |                       |                                    |                               | < 0.001       |
| Total cholesterol (mg/dL) | 187.2 ± 0.30                | 184.3 ± 0.32                       | 198.6 ± 0.58                  | < 0.001       |
| Triglyceride (mg/dL) | 134.4 ± 0.91                | 117.7 ± 0.81                       | 201.0 ± 2.50                  | < 0.001       |
| HDL cholesterol (mg/dL) | 48.8 ± 0.30                 | 50.4 ± 0.11                        | 42.6 ± 0.14                   | < 0.001       |
| Fasting glucose (mg/dL) | 96.7 ± 0.16                 | 93.6 ± 0.15                        | 109.2 ± 0.42                  | < 0.001       |
| Hemoglobin A1C (mg/dL) | 5.86 ± 0.01                 | 5.69 ± 0.01                        | 6.40 ± 0.29                   | < 0.001       |

Data are presented as percent (standard error) or mean ± standard deviation.
BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein.
*Unweighted number.
HDL cholesterol (42.6 vs. 50.4 mg/dL, \( P < 0.001 \)) was higher in subjects without metabolic syndrome whereas laboratory findings such as total cholesterol (198.6 vs. 184.3 mg/dL, \( P < 0.001 \)), TG (201.0 vs. 117.7 mg/dL, \( P < 0.001 \)), fasting glucose (109.2 vs. 93.6 mg/dL, \( P < 0.001 \)), and hemoglobin A1c (6.40 vs. 5.69 mg/dL, \( P < 0.001 \)) were higher in subjects with metabolic syndrome than in those without metabolic syndrome.

**Association between current wheezing and metabolic syndrome**

As shown in Table 2, subjects with metabolic syndrome were more likely to have lifetime asthma (adjusted odds ratio [aOR] = 1.30; 95% confidence interval [95% CI] = 1.12–1.51), physician-diagnosed asthma (aOR = 1.26; 95% CI = 1.07–1.49), or current asthma (aOR = 1.29; 95% CI = 1.04–1.58) compared to those without. In addition, subjects with metabolic syndrome more frequently had wheezing in the previous year (aOR = 1.56; 95% CI = 1.37–1.77) and wheezing during exercise in the previous year (aOR = 1.59; 95% CI = 1.37–1.84).

Table 3 summarizes the OR of the individual components of metabolic syndrome for the presence of current wheezing. In both models 1 and 2, central obesity (aOR = 1.51; 95% CI = 1.35–1.69 in model 1 and aOR = 1.48; 95% CI = 1.31–1.66 in model 2) and low HDL cholesterol (aOR = 1.24; 95% CI = 1.11–1.40 in model 1 and aOR = 1.18; 95% CI = 1.05–1.34 in model 2) were associated with current wheezing.

| Table 2. The odds ratio of the presence of metabolic syndrome for asthma status and wheezing |
| --- |
| **Variables** | **Crude model** | **Adjusted model** |
| | Non-metabolic syndrome | Metabolic syndrome | Non-metabolic syndrome | Metabolic syndrome |
| Lifetime asthma | Reference | 1.62 (1.40–1.87) | Reference | 1.30 (1.12–1.51) |
| Physician-diagnosed asthma | Reference | 1.53 (1.30–1.80) | Reference | 1.26 (1.07–1.49) |
| Current asthma | Reference | 1.95 (1.59–2.39) | Reference | 1.29 (1.04–1.58) |
| Current wheezing | Reference | 1.73 (1.54–1.96) | Reference | 1.56 (1.37–1.77) |
| Current exercise-induced wheezing | Reference | 1.58 (1.38–1.82) | Reference | 1.59 (1.37–1.84) |

Data are presented as an adjusted odds ratio (95% confidence interval).

*Adjusted for age, sex, and smoking status.

| Table 3. Odds ratio of the individual components of the metabolic syndrome for current wheezing: associations between the individual components of metabolic syndrome and current wheezing |
| --- |
| **Variables** | **Model 1** | **Model 2** |
| Age, increasing by 10 years | 1.19 (1.15–1.24) | 1.15 (1.10–1.20) |
| Sex | | |
| Male | Reference | Reference |
| Females | 1.60 (1.35–1.91) | 1.47 (1.23–1.76) |
| Smoking status | | |
| Never smoker | Reference | Reference |
| Current smoker | 3.14 (2.64–3.75) | 3.17 (2.66–3.80) |
| Ex-smoker | 1.44 (1.14–1.82) | 1.47 (1.16–1.87) |
| Central obesity*** | 1.51 (1.35–1.69) | 1.48 (1.31–1.66) |
| Dyslipidemia (TG)§§ | 1.08 (0.96–1.23) | 0.94 (0.82–1.07) |
| Dyslipidemia (HDL)‖‖ | 1.24 (1.11–1.40) | 1.18 (1.05–1.34) |
| High BP¶¶ | 1.13 (0.99–1.28) | 1.05 (0.92–1.20) |
| High FPG** | 1.09 (0.96–1.24) | 1.00 (0.88–1.14) |

Data are presented as an adjusted odds ratio (95% confidence interval).

TG, triglyceride; HDL, high-density lipoprotein; BP, blood pressure; FPG, fasting plasma glucose.

*Model 1: the individual components of metabolic syndrome age, sex, or smoking status were included. *Model 2: all components of metabolic syndrome age, sex, and smoking status were included. **Central obesity is defined as waist circumference ≥ 90 cm for males and ≥ 80 cm for females. ‡‡Dyslipidemia was defined as TG level ≥ 150 mg/dL. The subjects who are taking lipid-lowering agents were excluded. §§Dyslipidemia was defined as HDL cholesterol < 40 mg/dL in males and < 50 mg/dL in females. The subjects who are taking lipid-lowering agents were not included. ¶¶High BP was defined as systolic blood pressure ≥ 130 mmHg, diastolic blood pressure ≥ 85 mmHg, or treatment of previously diagnosed hypertension. **High FPG ≥ 100 mg/dL or previously diagnosed type 2 diabetes mellitus.

https://e-aair.org

https://doi.org/10.4168/aair.2021.13.5.808

812
were significantly associated with the presence of current wheezing. However, there were no significant associations between other components of metabolic syndrome (high TG, BP, and FPG level) and the presence of wheezing in either model 1 or 2.

**The additive effect of central obesity and low HDL cholesterol level for the presence of wheezing**

The rate of current wheezing according to the presence of central obesity and the HDL cholesterol level (high or low) is shown in Fig. 2. The rate of current wheezing in the central obesity group/low HDL cholesterol group was highest at 8.7%, followed by 7.9% in the central obesity/high HDL cholesterol group. Current wheezing was at 6.2% in the non-central obesity/low HDL cholesterol group and lowest at 5.0% in the non-central obesity/high HDL cholesterol group.

There was a dose-dependent association between low HDL cholesterol level and central obesity and the presence of wheezing. The adjusted OR for wheezing was highest when both central obesity and low HDL cholesterol were present (aOR = 1.67; 95% CI = 1.44–1.94), which was followed by when only central obesity was present (aOR = 1.45; 95% CI = 1.27–1.74) or low HDL cholesterol (aOR = 1.19; 95% CI = 1.03–1.39) were present.

**DISCUSSION**

We investigated the relationship between the individual components of metabolic syndrome and current wheezing. In this study, we identified 2 major findings. One is that current wheezing was observed much more frequently in subjects with metabolic syndrome in comparison to those without. The other is that, of the components of metabolic syndrome, central obesity and low HDL cholesterol were significantly associated with the presence of current wheezing. Moreover, the co-existence of central obesity and low HDL cholesterol has additive effects on wheezing in adults.

Many previous studies have indicated the relationship between metabolic syndrome and asthma or asthma symptoms, and have shown that metabolic syndrome is associated with...
asthma, as well as lung function impairment or asthma-like symptoms such as wheezing, resting dyspnea, or exercise-induced dyspnea. For example, Lee et al. showed that abdominal obesity, a major component of metabolic syndrome, is significantly associated with wheezing. However, the study population was localized to certain cities, and the age range was limited. Our study overcomes these limitations by analyzing a nationwide representative sample. The high correlation between central obesity and BMI is in line with previous findings that increased BMI is associated with increased risk of incident asthma. However, since data are limited regarding the role of central obesity and wheezing in different BMI categories (e.g., central obesity can also be present in normal or underweight population), future studies are needed for this issue.

Metabolic syndrome consists of various metabolic components, such as central adiposity, high BP, abnormal level of cholesterol, and uncontrolled state of the blood sugar level. Previous studies have dealt with the relationship between the individual components of metabolic syndrome and wheezing. One cross-sectional study in the US assessed the relationship between 3 cholesterol states (total cholesterol, HDL cholesterol, and non-HDL cholesterol) and wheezing. In that study, serum total cholesterol and non-HDL cholesterol levels were related to wheezing in the US population. Another large-cohort Spanish study assessed whether the components of metabolic syndrome are associated with wheezing and showed that high serum TG and low serum HDL cholesterol levels were associated with wheezing. In our study, low HDL cholesterol level was related with current wheezing in adults. Along with previous findings, our study supports the previous hypothesis suggesting a significant link between cholesterol, inflammation, and asthma. Interestingly, the type of cholesterol associated with current wheezing differed by country, and the reasons may be differences in racial and genetic factors, eating habits, and socioeconomic factors. Additional studies are needed to clarify the reasons for this phenomenon. In addition, we need to reveal whether this difference can be associated with different presentation and prognosis of asthma.

Our study is noteworthy in that we provide data showing the additive effect of central obesity and low HDL cholesterol on asthma. As previous studies separately evaluated the relationship between the individual components of metabolic syndrome and wheezing, the additive effects of the components of metabolic syndrome on asthma have not been identified. Our study results provide an important clinical implication that control of both lipid profiles and obesity may be more effective for prevention and treatment of asthma with the obesity phenotype.

The use of a large, nationwide sample of Korean adults across all age groups is one of the major advantages of our study. However, this advantage also becomes a limitation in that our study results may not be generalizable to subjects in other countries or ethnic groups. Secondly, our study is cross-sectional. Due to the study design, we could not clarify a causal relationship between the individual components of metabolic syndrome and current wheezing. Well-designed prospective studies are needed to clarify the causal relationship. Thirdly, our analysis focusing on wheezing episodes may overestimate the association between metabolic syndrome and asthma, since wheezing can be present in conditions other than asthma, such as obesity and vocal cord palsy. However, given that asthma is underdiagnosed in Korea, the analysis focusing on wheezing episodes would be more sensitive to defining symptomatic subjects with asthma compared to other methods.

In conclusion, we show the association between the individual components of metabolic syndrome and wheezing in a nationwide population cohort. Low HDL cholesterol level
and central obesity had a meaningful effect on current wheezing, while other components of metabolic syndrome did not show a significant relationship. In addition, we found the association of wheezing to be much stronger when central obesity and low HDL cholesterol are present together.

ACKNOWLEDGMENTS

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Ministry of Science, Information and Communications Technologies (No. NRF-2020R1F1A1070468 and 2021M3E5D1A0101517621) and the Korea Medical Device Development Fund grant funded by the Korea government (the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, the Ministry of Health & Welfare, the Ministry of Food and Drug Safety) (No. KMDF202014X08-03).

REFERENCES

1. Pucci G, Alcidi R, Tap L, Battista F, Mattace-Raso F, Schillaci G. Sex- and gender-related prevalence, cardiovascular risk and therapeutic approach in metabolic syndrome: a review of the literature. Pharmacol Res 2017;120:34-42.
2. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005;365:1415-28.
3. Baffi CW, Wood L, Winnica D, Strollo PJ Jr, Gladwin MT, Que LG, et al. Metabolic syndrome and the lung. Chest 2016;149:1525-34.
4. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JJ, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5.
5. Brumpton BM, Camargo CA Jr, Romundstad PR, Langhammer A, Chen Y, Mai XM. Metabolic syndrome and incidence of asthma in adults: the HUNT study. Eur Respir J 2013;42:1495-502.
6. Tomita Y, Fukutomi Y, Irie M, Azekawa K, Hayashi H, Kamide Y, et al. Obesity, but not metabolic syndrome, as a risk factor for late-onset asthma in Japanese women. Allergol Int 2019;68:240-6.
7. Morjaria JB, Rigby AS, Morice AH. Asthma phenotypes: do cough and wheeze predict exacerbations in persistent asthma? Eur Respir J 2017;50:1701366.
8. Uzunulu M, Oguz A, Gedik C, Asian G, Arik S. Is prevalence of metabolic syndrome high in patients with asthma? Acta Clin Belg 2011;66:49-52.
9. Park S, Choi NK, Kim S, Lee CH. The relationship between metabolic syndrome and asthma in the elderly. Sci Rep 2018;8:9378.
10. Fenger RV, Gonzalez-Quintela A, Linneberg A, Husemoen LL, Thuesen BH, Aadahl M, et al. The relationship of serum triglycerides, serum HDL, and obesity to the risk of wheezing in 85,555 adults. Respir Med 2013;107:816-24.
11. Zimmet P, M M Alberti KG, Serrano Rios M. A new international diabetes federation worldwide definition of the metabolic syndrome: the rationale and the results. Rev Esp Cardiol 2005;58:1371-6.
12. Leone N, Courbon D, Thomas F, Bean K, Jégo B, Leynaert B, et al. Lung function impairment and metabolic syndrome: the critical role of abdominal obesity. Am J Respir Crit Care Med 2009;179:509-16.

13. Lee EI, In KH, Ha ES, Lee KJ, Hur GY, Kang EH, et al. Asthma-like symptoms are increased in the metabolic syndrome. J Asthma 2009;46:339-42.

14. Fessler MB, Massing MW, Spruell B, Jaramillo R, Draper DW, Madenspacher JH, et al. Novel relationship of serum cholesterol with asthma and wheeze in the United States. J Allergy Clin Immunol 2009;124:967-974.e1-15.

15. Peters U, Dixon AE, Forno E. Obesity and asthma. J Allergy Clin Immunol 2018;141:1169-79.

16. Camargo CA Jr, Weiss ST, Zhang S, Willett WC, Speizer FE. Prospective study of body mass index, weight change, and risk of adult-onset asthma in women. Arch Intern Med 1999;159:2582-8.

17. Beuther DA, Sutherland ER. Overweight, obesity, and incident asthma: a meta-analysis of prospective epidemiologic studies. Am J Respir Crit Care Med 2007;175:661-6.

18. Gilliland FD, Berhane K, Islam T, McConnell R, Gauderman WJ, Gilliland SS, et al. Obesity and the risk of newly diagnosed asthma in school-age children. Am J Epidemiol 2003;158:406-15.

19. Scichilone N, Rizzo M, Benfante A, Catania R, Giglio RV, Nikolic D, et al. Serum low density lipoprotein subclasses in asthma. Respir Med 2013;107:1866-72.

20. Kim BK, Park SY, Ban GY, Kim MA, Lee JH, An J, et al. Evaluation and management of difficult-to-treat and severe asthma: an expert opinion from the Korean Academy of Asthma, Allergy and Clinical Immunology, the Working Group on Severe Asthma. Allergy Asthma Immunol Res 2020;12:910-33.